Full-Time

Senior R&D Engineer

Instruments

Confirmed live in the last 24 hours

Calyxo

Calyxo

51-200 employees

Develops medical devices for kidney stone treatment

Compensation Overview

$135k - $165k/yr

+ Stock Options

Senior

Pleasanton, CA, USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
GD&T
Autodesk CFD
SolidWorks
Requirements
  • Bachelor’s degree in Mechanical Engineering, Biomedical Engineering, or a related field, and a minimum of 5 years of medical device experience, OR
  • Advanced degree in a related field and a minimum of 4 years of medical device experience
  • Understanding of medical device regulations, including ISO 13485 and FDA 21 CFR Part 820.
  • Ability to apply DFX principles to create designs that can scale.
  • Proficiency in SolidWorks and a strong understanding of design for manufacturability, tolerance stack analysis, and GD&T.
  • Track record of taking design concepts from prototyping stage through to design maturation.
  • Proven design capabilities in two or more of the following key areas: injection molding, electro-mechanical sub-systems, catheter construction, endoscope construction, fluidics.
  • Experience creating and running simulations (CFD, FEA) to inform product development.
  • Solid experience conducting structured design of experiments (DOEs) and using statistical methods to analyze data.
  • Strong collaboration and communication skills, with the ability to work effectively on cross-functional teams.
  • Strong problem-solving and analytical skills, with a hands-on approach to product development and testing.
  • Experience in product development within regulated industries and knowledge of sterilization and biocompatibility testing.
Responsibilities
  • Create prototypes, design fixturing, devise feasibility studies, and execute testing to draw meaningful conclusions and guide product development.
  • Ensure design and development pathways maintain adherence to the design control process, working with cross-functional partners to enable manufacturability, reliability, and scalability.
  • Use SolidWorks to create well-defined models, assemblies, and engineering drawings.
  • Effectively solve engineering problems through methodical root cause analysis and data-driven solution finding.
  • Define qualification strategies for new designs or processes, working in partnership with other teams across the organization to gain alignment.
  • Meaningfully translate customer requirements into new or revised product requirements and engineering specifications.
  • Drive communication with suppliers to progress activities relevant to component or subassembly development.
  • Effectively communicate project progress, results, and risks to relevant stakeholders.
  • Develop and validate verification test methods, create and execute protocols, and author associated reports and risk documentation.
  • Coordinate external testing activities such as sterilization, packaging, and biocompatibility testing, ensuring alignment with project goals and timelines.

Calyxo develops medical devices specifically designed to treat kidney stones. Their products focus on improving the effectiveness and safety of treatment options available to urologists. By collaborating with leading urologists, Calyxo ensures that their devices meet the real clinical needs of healthcare providers. Unlike many competitors, Calyxo emphasizes a strong partnership with medical professionals to enhance patient care and clinical outcomes. The company's goal is to provide advanced solutions that enable urologists to treat kidney stones more efficiently, ultimately improving the overall experience for patients.

Company Size

51-200

Company Stage

Series D

Total Funding

$97.2M

Headquarters

Pleasanton, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA clearance for the redesigned CVAC System boosts market credibility and adoption.
  • Rising prevalence of kidney stones expands Calyxo's potential customer base.
  • Series D funding of $50M supports further innovation and market expansion.

What critics are saying

  • Emerging competition may impact Calyxo's market share in kidney stone treatments.
  • Economic downturns could reduce healthcare spending on new medical devices.
  • Rapid technological advancements require Calyxo to continuously innovate to stay competitive.

What makes Calyxo unique

  • Calyxo's CVAC System offers superior stone clearance compared to standard URS.
  • The company focuses on minimally invasive kidney stone treatments with high patient satisfaction.
  • Calyxo collaborates with leading urologists to enhance R&D and device innovation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

-7%
Business Wire
May 14th, 2024
Study Presented At Aua Shows Superior Kidney Stone Clearance Rates For Sure Procedure Using Calyxo’S Cvac System Vs Standard Urs

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio. The CVAC System, a revolutionary technology that is designed for complete kidney stone removal, was the focus of the prospective, randomized, multi-center ASPIRE study, which compared the safety and efficacy of steerable ureteroscopic renal evacuation (SURE) vs ureteroscopy (URS) with basketing. The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco. In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS. Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden. Safety was comparable between groups

Business Wire
Mar 26th, 2024
Calyxo Announces Fda Clearance For New, Redesigned Cvac System

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment. More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback. Clinical studies have shown that residual stone fragments are associated with a 20%-44% incidence of post-procedure problems, including pain, infection, emergency department visits, hospitalization and need for retreatment. Steerable ureteroscopic renal evacuation (SURE) using the original CVAC Aspiration System has been used to successfully treat more than 1,500 patients in the U.S., demonstrating that vacuum aspiration of stone fragments improves clinical outcomes, with 97% volumetric stone clearance and a high likelihood of avoiding the need for a secondary or more invasive procedure (according to clinical study data collected in patients treated with the device)

Finsmes
Dec 12th, 2023
Calyxo Raises $50M in Series D Funding

Calyxo, a Pleasanton, CA-based medical device company developing next-generation treatment solutions for patients with kidney stones, raised $50M in Series D funding.

Questa Capital
Jul 6th, 2022
Questa Capital invests into Calyxoinc in $32.7M

Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG.

Business Wire
Jul 6th, 2022
Calyxo Raises $32.7 Million In Series C Financing To Support Novel Approach To Treating Kidney Stones

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG. Calyxo has developed the innovative CVAC Aspiration System that utilizes irrigation and aspiration to remove kidney stones with the goal of a surgically stone-free outcome, a challenge that has always been difficult to achieve consistently